Twist Bioscience (NASDAQ:TWST) Price Target Raised to $54.00 at Scotiabank

Twist Bioscience (NASDAQ:TWST - Free Report) had its target price upped by Scotiabank from $50.00 to $54.00 in a research report report published on Tuesday morning,Benzinga reports. They currently have a sector outperform rating on the stock.

Other analysts have also recently issued research reports about the stock. Evercore ISI increased their price target on shares of Twist Bioscience from $52.00 to $56.00 and gave the company an "outperform" rating in a research note on Tuesday, October 1st. JPMorgan Chase & Co. lifted their price target on Twist Bioscience from $28.00 to $35.00 and gave the stock an "underweight" rating in a report on Monday, August 5th. Robert W. Baird lifted their target price on Twist Bioscience from $46.00 to $48.00 and gave the stock an "outperform" rating in a research note on Tuesday. Barclays dropped their price target on Twist Bioscience from $60.00 to $55.00 and set an "overweight" rating on the stock in a research note on Monday, August 5th. Finally, Leerink Partners lifted their price objective on shares of Twist Bioscience from $45.00 to $48.00 and gave the stock a "market perform" rating in a research report on Thursday, October 17th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat.com, Twist Bioscience presently has an average rating of "Moderate Buy" and a consensus target price of $51.78.

Twist Bioscience Trading Down 0.3 %

Shares of Twist Bioscience stock traded down $0.11 during trading hours on Tuesday, reaching $41.32. 1,235,906 shares of the company's stock were exchanged, compared to its average volume of 953,744. The company has a 50 day moving average of $43.99 and a two-hundred day moving average of $46.18. Twist Bioscience has a fifty-two week low of $23.00 and a fifty-two week high of $60.90. The stock has a market cap of $2.42 billion, a P/E ratio of -10.82 and a beta of 1.78.

Insider Transactions at Twist Bioscience

In related news, Director Robert Chess sold 3,600 shares of the firm's stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $47.26, for a total transaction of $170,136.00. Following the transaction, the director now directly owns 21,641 shares of the company's stock, valued at approximately $1,022,753.66. This trade represents a 14.26 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Emily M. Leproust sold 14,334 shares of the business's stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $44.60, for a total transaction of $639,296.40. Following the completion of the sale, the chief executive officer now directly owns 589,552 shares of the company's stock, valued at $26,294,019.20. This represents a 2.37 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 98,118 shares of company stock valued at $4,391,151. 3.92% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Twist Bioscience

Hedge funds have recently added to or reduced their stakes in the stock. Signaturefd LLC grew its holdings in shares of Twist Bioscience by 63.0% during the 3rd quarter. Signaturefd LLC now owns 792 shares of the company's stock worth $36,000 after purchasing an additional 306 shares in the last quarter. EdgeRock Capital LLC acquired a new stake in Twist Bioscience during the second quarter worth about $43,000. Blue Trust Inc. increased its holdings in Twist Bioscience by 2,912.8% in the 2nd quarter. Blue Trust Inc. now owns 1,175 shares of the company's stock valued at $58,000 after buying an additional 1,136 shares during the period. DekaBank Deutsche Girozentrale acquired a new position in shares of Twist Bioscience in the 2nd quarter valued at approximately $61,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Twist Bioscience by 21.9% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company's stock worth $98,000 after acquiring an additional 381 shares in the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.